Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnin

Published Phase 1 data of SON-1010 in Frontiers in Immunology demonstrating the safety and tolerability of the F H AB-derived Interleukin 12 in healthy volunteersAnnounced early safety data from the company's Phase 1b/2a clinical trial of SON-080 in patients with chemotherapy-induced peripheral neuropathy (CIPN)Rece...

Related Keywords

India ,Australia ,New Jersey ,United States ,American ,Pankaj Mohan ,Jack Yauch ,Jay Cross ,Securities Exchange ,Sonnet Biotherapeutics Inc ,Exchange Commission ,Solebury Strategic Communications ,Jersey Technology Business Tax Certificate Transfer Program ,American Association For Cancer Research ,Sonnet Biotherapeutics Holdings Inc ,Nasdaq ,Published Phase ,American Association ,Cancer Research ,Sonnet Founder ,Chief Executive ,Recent Corporate ,Data Safety Monitoring Board ,Diabetic Peripheral Neuropathy ,Dose Interleukin ,Quarter Ended March ,Fully Human Albumin Binding ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Months Ended March ,